Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
Phase 4
Completed
- Conditions
- Pterygia
- Registration Number
- NCT00383396
- Lead Sponsor
- Innovative Medical
- Brief Summary
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- pts with symptomatic pterygia unresponsive to palliative treatment.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cyclosporine's anti-inflammatory effects on pterygia ocular surfaces?
How does topical cyclosporine 0.05% BID compare to corticosteroids in managing pterygia-related inflammation?
Which biomarkers correlate with cyclosporine response in pterygia patients with chronic ocular surface inflammation?
What are the long-term adverse events of cyclosporine 0.05% in NCT00383396 Innovative Medical trial?
Are there combination therapies involving cyclosporine for pterygia recurrence prevention in post-surgical patients?
Trial Locations
- Locations (1)
Dr. Schechter
🇺🇸Boynton Beach, Florida, United States
Dr. Schechter🇺🇸Boynton Beach, Florida, United States